{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["639(8054)"],"submitter":["Jebran AF"],"pubmed_abstract":["Cardiomyocytes can be implanted to remuscularize the failing heart<sup>1-7</sup>. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques. After confirmation of in vitro and in vivo (nude rat model) equivalence of the newly developed rhesus macaque EHM model with a previously established Good Manufacturing Practice-compatible human EHM formulation<sup>8</sup>, long-term retention (up to 6 months) and do"],"journal":["Nature"],"pagination":["503-511"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11903342"],"repository":["biostudies-literature"],"pubmed_title":["Engineered heart muscle allografts for heart repair in primates and humans."],"pmcid":["PMC11903342"],"pubmed_authors":["Boretius S","Mietsch M","Strobel P","Bremmer F","Stauske M","Zhang L","Kaulfuß S","Baraki H","Gruber-Dujardin E","Meyer T","Fujita B","Seidler T","Yang H","Moussavi A","Zimmermann WH","Voigt JU","Drummer C","Walter L","Diecke S","Didie M","Kowallick J","Roshani B","Daskalaki M","Fischer A","Wollnik B","Kutschka I","Sakib MS","Dressel R","Hinkel R","Jebran AF","Levent E","Mißbach S","Ritter CO","Qin X","Kensah G","Hasenfuß G","Riggert J","Legler T","Petersen B","Lotz J","Maetz-Rensing K","Bleyer M","Roos C","Hellenkamp K","Yigit G","Tiburcy M","Wu JC","Hasenauer C","Kruger D","Ensminger S","Rodriguez-Polo I","Stahl-Henning C","Nette T","Kaurani L","Behr R"],"additional_accession":[]},"is_claimable":false,"name":"Engineered heart muscle allografts for heart repair in primates and humans.","description":"Cardiomyocytes can be implanted to remuscularize the failing heart<sup>1-7</sup>. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques. After confirmation of in vitro and in vivo (nude rat model) equivalence of the newly developed rhesus macaque EHM model with a previously established Good Manufacturing Practice-compatible human EHM formulation<sup>8</sup>, long-term retention (up to 6 months) and do","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-02T21:05:28.884Z","creation":"2025-04-03T23:57:20.417Z"},"accession":"S-EPMC11903342","cross_references":{"pubmed":["39880949"],"doi":["10.1038/s41586-024-08463-0"]}}